Robert Lending, MD
Internal Medicine · Tucson, AZNPI 1154389807
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,800 of the $10,733 with a category attached, or 63.4%. Amgen accounts for 72.5% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $7,648 and has fallen 92.3% since, to $590 in 2025. Among internal medicine clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 170 payments — averaging $63.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$8K
- Amarin Pharma, Inc.$575
- Chiesi USA, Inc.$322
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$230
- GSK$208
- Medicure Pharma Inc.$199
- plus $1K from 21 others
Across 37 payments — averaging $2613.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$33K
- Kowa Research Institute, Inc.$29K
- AstraZeneca$21K
- Astrazeneca UK Limited$11K
- Pfizer$3K
What the payments were for
- Speaking & faculty fees$6,80063%
- Travel & lodging$170%
- Food & beverage$3,90536%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 52 | $7,785 |
| Amarin Pharma, Inc. | 24 | $575 |
| Chiesi USA, Inc. | 2 | $322 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $230 |
| GSK | 7 | $208 |
| Medicure Pharma Inc. | 5 | $199 |
| AstraZeneca(2 entities) | 10 | $159 |
| Novartis | 9 | $154 |
| Boston Scientific | 1 | $150 |
| Kowa Pharmaceuticals America, Inc. | 7 | $149 |
| Exact Sciences | 7 | $127 |
| Merck | 7 | $125 |
| Kestra Medical Technology Services, Inc. | 1 | $121 |
| Sanofi-aventis U.S. LLC | 1 | $88 |
| Pfizer | 5 | $71 |
| Regeneron Healthcare Solutions, Inc. | 3 | $55 |
| Radius Health, Inc. | 2 | $40 |
| Novo Nordisk | 2 | $33 |
| Johnson & Johnson | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Averitas Pharma Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Amryt Pharma Holdings Ltd | 1 | $15 |
| Biogen | 1 | $13 |
| Digestive Care, Inc. | 1 | $12 |
| Travere Therapeutics, Inc. | 5 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$6,617
- JUXTAPID$300
- EVENITY$250
- Vascepa$238
- WATCHMAN FLX$150
- AREXVY$122
- Assure WCD$121
How this compares
$10,733 in reported general payments places this provider in the 95th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 45 | $56,068 |
| Repatha SureclickEvolocumab | 26 | $31,552 |
| JanuviaSitagliptin Phosphate | 13 | $19,926 |
| VascepaIcosapent Ethyl | 14 | $13,633 |
| LivaloPitavastatin Calcium | 13 | $5,564 |
| SynthroidLevothyroxine Sodium | 30 | $3,195 |
| Rosuvastatin Calcium | 132 | $1,517 |
| Ezetimibe | 50 | $1,457 |
| Colchicine | 11 | $1,308 |
| Levothyroxine Sodium | 98 | $1,271 |
| Valsartan | 23 | $1,227 |
| Atorvastatin Calcium | 111 | $1,021 |
| Fenofibrate | 31 | $875 |
| Niacin ErNiacin | 13 | $864 |
| Metoprolol Succinate | 50 | $858 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $71 | $56,06845 claims |
| MerckJanuvia | $125 | $19,92613 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $149 | $5,56413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Tucson
- Rajesh JanardhananTucson$685K
- Mona SelejTucson$440K
- Franz RischardTucson$55K
- Nebojsa SkrepnikTucson$48K
- Christine OxleyTucson$44K
- Muhammad HusnainTucson$19K
- Steven WoolTucson$19K
- Surekha BandlamuriTucson$17K
- Augusto PosadasTucson$15K
- Lisa EmmansTucson$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.